TOP TEN perturbations for 1552576_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1552576_at
Selected probe(set): 1552576_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1552576_at (1552576_at) across 6672 perturbations tested by GENEVESTIGATOR:

influenza virus study 11 (A/H5N3) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-1.1418171
Number of Samples:3 / 3
Experimental influenza virus study 11 (A/H5N3)
Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F119/3/1997(H5N3). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

influenza virus study 9 (A/pH1N1) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-1.1189795
Number of Samples:3 / 3
Experimental influenza virus study 9 (A/pH1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype [A/Singapore/478/2009 (pH1N1)]. Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

glioma study 17 ( small cell glioblastoma; unsorted) / non-tumor cortical tissue

Relative Expression (log2-ratio):-1.0294828
Number of Samples:2 / 4
Experimental glioma study 17 ( small cell glioblastoma; unsorted)
Brain cells isolated from high grade small cell glioblastoma (grade IV). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation. Patients were 56 ± 3 years old males.
Control non-tumor cortical tissue
Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses.

exercise study 33 (YT; fast twitch; pre-exerc.) / exercise study 33 (YUT; fast twitch; pre-exerc.)

Relative Expression (log2-ratio):1.0042534
Number of Samples:6 / 4
Experimental exercise study 33 (YT; fast twitch; pre-exerc.)
Fast twitch myosin heavy chain muscle fibers (MHC) IIa were obtained from vastus lateralis muscle. Biopsies were taken from young trained (YT) women (23±2 years old) before the 36th (last) exercise session. Participants underwent 12 weeks of progressive resistance training including 36 training sessions (3 days/week) with three sets of 10 bilateral knee extensions at 70–75% of their one-repetition maximum (1 RM). Fibers were separated under the light microscope and MHC isoform was determinated based on SDS-PAGE analysis. Exclusion criteria: acute/chronic illness, cardiac, pulmonary, liver, or kidney abnormalities, uncontrolled hypertension, insulin or non-insulin-dependent diabetes, abnormal blood, or urine chemistries, arthritis, a history of neuromuscular problems, tobacco smoking. Individuals, that had ever completed any formal exercise programs or physical activity outside of their activities of daily living, were excluded as well.
Control exercise study 33 (YUT; fast twitch; pre-exerc.)
Fast twitch myosin heavy chain muscle fibers (MHC) IIa were obtained from vastus lateralis muscle. Biopsies were taken from young untrained (YUT) women (23±2 years old) before the first exercise. Fibers were separated under the light microscope and MHC isoform was determinated based on SDS-PAGE analysis. Exclusion criteria: acute/chronic illness, cardiac, pulmonary, liver, or kidney abnormalities, uncontrolled hypertension, insulin or non-insulin-dependent diabetes, abnormal blood, or urine chemistries, arthritis, a history of neuromuscular problems, tobacco smoking. Individuals, that had ever completed any formal exercise programs or physical activity outside of their activities of daily living, were excluded as well.

influenza virus study 9 (A/H9N2) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-0.98422813
Number of Samples:3 / 3
Experimental influenza virus study 9 (A/H9N2)
Human carcinoma cell line A549 infected with influenza A virus subtype A/Duck/Malaysia/01 (H9N2). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

influenza virus study 9 (A/H5N2) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-0.9613571
Number of Samples:3 / 3
Experimental influenza virus study 9 (A/H5N2)
Human carcinoma cell line A549 infected with influenza A virus subtype A/duck/Malaysia/F118/08/2004(H5N2). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

engineered skin substitute study 2 (intermediate) / engineered skin substitute study 1 (intermediate)

Relative Expression (log2-ratio):0.92021847
Number of Samples:6 / 3
Experimental engineered skin substitute study 2 (intermediate)
Human skin substitutes tissue samples collected after 14 and 28 days after transplantation to athymic mice.
Control engineered skin substitute study 1 (intermediate)
Human skin substitutes tissue samples collected after 7 days in culture.

hepatitis C study 4 (under treatment; responder) / hepatitis C study 4 (before treatment)

Relative Expression (log2-ratio):0.881587
Number of Samples:16 / 27
Experimental hepatitis C study 4 (under treatment; responder)
Liver biopsy samples from chronic hepatitis C (CH-C) patients after treatment with interferon-alpha 2b (IFN-a 2b) and ribavirin (Rib) in combination. Patients received IFN-a 2b (6 MU, every day for 2 weeks, then three times a week for 22 weeks) and Ribavirin (10–13 mg/kg/day) combination therapy for 24 weeks. Individuals had treatment success and were for that responders after no HCV viremia detected at the cessation of therapy. There were two groups of responders: Those with sustained virologic response (SVR; clearance of HCV viremia at 24 weeks after cessation of therapy) and those with a transient response (TR; no detectable HCV viremia at 24 weeks but relapse during the follow-up period).
Control hepatitis C study 4 (before treatment)
Liver biopsy samples from chronic hepatitis C (CH-C) patients before treatment with interferon-alpha 2b (IFN-a 2b) and ribavirin (Rib).

influenza virus study 10 (A/H5N2) / influenza virus study 4 (A/H1N1)

Relative Expression (log2-ratio):-0.8713522
Number of Samples:3 / 3
Experimental influenza virus study 10 (A/H5N2)
Human carcinoma cell line A549 infected with influenza A virus subtype influenza virus A/duck/Malaysia/F189/07/2004(H5N2). Samples were taken 10 hours post-infection.
Control influenza virus study 4 (A/H1N1)
Human carcinoma cell line A549 infected with influenza A virus subtype A/WSN/33 (H1N1). Samples were taken 10 hours post-infection.

glioma study 17 (glioblastoma; unsorted) / non-tumor cortical tissue

Relative Expression (log2-ratio):-0.8635349
Number of Samples:2 / 4
Experimental glioma study 17 (glioblastoma; unsorted)
Brain cells isolated from high grade glioblastoma (grade IV). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation.
Control non-tumor cortical tissue
Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses.

Organism: Homo sapiens
Gene: 1552576_at
Selected probe(set): 214707_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1552576_at (214707_x_at) across 6672 perturbations tested by GENEVESTIGATOR:

kidney transplantation study 15 (8 week) / normal monocyte (CD14+) sample

Relative Expression (log2-ratio):2.333809
Number of Samples:2 / 5
Experimental kidney transplantation study 15 (8 week)
CD14+ monocyte samples derived from kidney transplant patients 8 weeks post-transplantation. Samples were collected 8 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal monocyte (CD14+) sample
CD14+ monocyte samples derived from healthy control subjects.

systemic lupus erythematosus study 13 (untreated) / normal PBMC sample

Relative Expression (log2-ratio):-1.8768635
Number of Samples:4 / 5
Experimental systemic lupus erythematosus study 13 (untreated)
Peripheral blood mononuclear cells (PBMCs) obtained from systemic lupus erythematosus (SLE) patients. Freshly isolated PBMCs were cultured in RPMI/10% FBS for 6 hours. Lupus patients fulfilled American College of Rheumatology classification criteria for disease, and disease activity was quantified by SLEDAI. Patients were excluded if they showed symptoms of recent or active infection or were pregnant. None of the patients was taking Pioglitazone or other PPAR-γ agonists.
Control normal PBMC sample
Peripheral blood mononuclear cells (PBMCs) obtained from healthy subjects. Freshly isolated PBMCs were cultured in RPMI/10% FBS for 6 hours.

prostate cancer study 7 ( met. crpc) / prostate cancer study 7 ( met. pca)

Relative Expression (log2-ratio):1.6911869
Number of Samples:2 / 3
Experimental prostate cancer study 7 ( met. crpc)
Metastatic lymph node tissue sample of male patients with androgen-independent carcinoma of the prostate (castration-resistant prostate carcinoma) with prior therapy.
Control prostate cancer study 7 ( met. pca)
Metastatic lymph node tissue sample of male patients with primary prostate carcinoma with no prior therapy.

atopic dermatitis study 21 (lesional; whole skin) / normal skin tissue

Relative Expression (log2-ratio):-1.6606731
Number of Samples:5 / 6
Experimental atopic dermatitis study 21 (lesional; whole skin)
Lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %.
Control normal skin tissue
Full thickness skin samples isolated from healthy subjects by laser capture microdissection.

OXPHOS disorder study 1 (old) / control muscle (old)

Relative Expression (log2-ratio):1.637949
Number of Samples:2 / 2
Experimental OXPHOS disorder study 1 (old)
Skeletal muscle biopsies obtained from young patients (50 and 68 years old) with oxidative phosphorylation system deficiency (OXPHOS disorder). All patients exhibited mutations in the catalytic DNA polymerase gamma (POLG1) gene.
Control control muscle (old)
Skeletal muscle biopsies obtained from control old subjects that were 53 and 64 years old.

colorectal adenoma study 2 / normal colon tissue

Relative Expression (log2-ratio):-1.6187372
Number of Samples:5 / 6
Experimental colorectal adenoma study 2
Laser microdissected human adenoma sample.
Control normal colon tissue
Laser microdissected human colonic epithelial cells sample.

ovarian tumor study 11 (low grade) / ovarian tumor study 11 (borderline)

Relative Expression (log2-ratio):1.5642395
Number of Samples:11 / 8
Experimental ovarian tumor study 11 (low grade)
Human microdissected tumor cells from the ovary of patients with low grade serous carcinoma.
Control ovarian tumor study 11 (borderline)
Human microdissected tumor cells from the ovary of patients with low-malignant (borderline) tumors of the ovary.

myotonic dystrophy study 4 (skeletal muscle; DM1) / normal skeletal muscle tissue (adult)

Relative Expression (log2-ratio):1.5517063
Number of Samples:5 / 6
Experimental myotonic dystrophy study 4 (skeletal muscle; DM1)
Unspecified skeletal muscle biopsies obtained from patients with myotonic dystrophy type 1 (DM1).
Control normal skeletal muscle tissue (adult)
Commercially purchased normal adult skeletal muscle tissue samples.

glioma study 17 (anaplastic astrocytoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)

Relative Expression (log2-ratio):-1.5494642
Number of Samples:2 / 3
Experimental glioma study 17 (anaplastic astrocytoma; A2B5+)
Oligodendrocyte progenitor cells (OPC) isolated from high grade anaplastic astrocytoma (grade III). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 45 ± 18 years old.
Control non-tumor oligodendrocyte progenitor cell sample (cortex)
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

prostate cancer study 7 ( met. pca) / prostate cancer study 7 (crpc)

Relative Expression (log2-ratio):-1.5466661
Number of Samples:3 / 7
Experimental prostate cancer study 7 ( met. pca)
Metastatic lymph node tissue sample of male patients with primary prostate carcinoma with no prior therapy.
Control prostate cancer study 7 (crpc)
Tumor tissue sample of male patients with androgen-independent carcinoma of the prostate (castration-resistant prostate carcinoma) with prior therapy.